Nephros, Inc. (NEPH) 

Nephros, Inc. develops and sells high performance water solutions to the medical and commercial markets in the United States. The company operates in three segments: Water Filtration, Pathogen Detection, and Renal Products. It offers ultrafiltration products that are used in dialysis centers for the removal of biological contaminants from water and bicarbonate concentrate; and in hospitals for the prevention of infection from waterborne pathogens, such as legionella and pseudomonas, as well as in military and outdoor recreation, commercial, and other healthcare facilities. The company also develops and sells real-time water testing systems to provide actionable data on waterborne pathogens; and medical device products for patients with renal disease, including a 2nd generation hemodiafiltration system for the treatment of patients with end stage renal disease. In addition, it offers water filters that improve the taste and odor of water, as well as reduce biofilm, bacteria, and scale build-up in downstream equipment under the Nephros and AETHER brands for the food service, hospitality, convenience store, and health care markets. The company was incorporated in 1997 and is headquartered in South Orange, New Jersey.

Show less

Over the last 12 months, insiders at Nephros, Inc. have bought $183,358 and sold $0 worth of Nephros, Inc. stock.

On average, over the past 5 years, insiders at Nephros, Inc. have bought $98,939 and sold $0 worth of stock each year.

Highest buying activity among insiders over the last 12 months: Banks Robert R. Jr. (President and CEO) — $155,052. Amron Arthur H (director) — $56,612.

The last purchase of 3,000 shares for transaction amount of $6,735 was made by Amron Arthur H (director) on 2024‑05‑30.